カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

連続バイオプロセッシングのグローバル市場予測（～2028）：クロマトグラフィー、ろ過、バイオリアクター、培地

◆英語タイトル：Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028

MarketsandMarketsが発行した調査報告書（PH8866-24）◆商品コード：PH8866-24
◆発行会社（リサーチ会社）：MarketsandMarkets
◆発行日：2023年11月23日
◆ページ数：263
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：バイオ
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥742,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥997,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,222,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

“世界の連続バイオプロセッシング市場は、2023年の218百万米ドルから2028年には599百万米ドルに達し、2023年から2028年の予測期間中のCAGRは22.4％になると予測”この市場の成長は、CDMOやCMOの間で連続バイオプロセッシングの採用が増加していることに起因しています。連続バイオプロセッシングは、CDMOやCMOの間でバイオ医薬品製造のために普及しています。これらの組織は、バイオ医薬品をより迅速かつ効率的に製造するというプレッシャーの高まりに直面しており、連続バイオプロセッシングはこの需要に応えるのに役立ちます。さらに、連続バイオプロセッシングは、より大規模なプロジェクトや新たな治療領域へと移行しつつあります。この傾向は、今後数年間、連続バイオプロセッシング市場の成長を促進すると予想されます。

“2022年の用途別シェアはモノクローナル抗体分野が最大”
2022年、世界の連続バイオプロセッシング市場において、モノクローナル抗体セグメントがアプリケーション別で最大のシェアを占めました。連続バイオプロセッシングは、モノクローナル抗体のバイオプロセスにおいて急速に勢いを増しており、施設の設置面積の縮小、投資コストの削減、柔軟性、プロセスの経済性といった潜在的な利点を提供します。哺乳類細胞由来のモノクローナル抗体の商業的成功は、より高い生産性と柔軟性を提供し、コストを削減する新しいシングルユースバイオリアクターシステムに対する需要の高まりにつながりました。

“2023-2028年の予測期間中、アメリカが連続バイオプロセッシング市場をリードし続ける見込み”
2022年の北米における連続バイオプロセッシング市場はアメリカがリードしました。アメリカはバイオ医薬品の主要市場であり、世界市場の約3分の1を占めています。バイオ医薬品研究開発の世界的リーダーでもあります。製薬研究製造者協会（PhRMA）によると、アメリカの製薬会社はほとんどの新薬の知的財産権を保有しており、世界の医薬品研究開発の半分以上を実施しています。アメリカのバイオプロセス企業は、連続バイオプロセッシングを用いたバイオ医薬品の開発に積極的に参加しています。また、これらの企業は、ターンアラウンドタイムが短く、エネルギー効率の高い灌流ベースの製品を広く提供しています。これらの要因が、同国の連続バイオプロセッシング市場の成長を支えています。

本レポートのために実施した一次インタビューは以下のように分類されます：
- 回答者別：供給側70％、需要側30％
- 役職別：管理職45％、CXOおよび取締役30％、経営幹部25％
- 地域別：北米40％、ヨーロッパ25％、アジア太平洋20％、中南米10％、中東・アフリカ5％

レポート掲載企業一覧は以下の通りです：
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Sartorius AG (Germany)
- Thermo Fisher Scientific Inc. (US)
- Repligen Corporation (US)
- Merck KGaA (Germany)
- 3M Company (US)
- Getinge AB (Sweden)
- Eppendorf SE (Germany)
- Corning Incorporated (US)
- Entegris (US)
- FUJIFILM Holdings Corporation (Japan)
- Meissner filtration products, Inc. (US)
- Kühner AG (Switzerland)
- Esco Lifesciences Group (Singapore)
- SATAKE MultiMix Corporation (Japan)
- Bionet (Spain)
- Stobbe Group (Switzerland)
- bbi-biotech GmbH (Germany)
- OmniBRx Biotechnologies (India)
- Cell Culture Company, LLC (US)
- Pierre Guérin (France)
- Solida Biotech GmbH (Germany)
- Zellwerk GmbH (Germany)
- 3D Biotek, LLC (US)
- FiberCell Systems Inc. (US)

調査範囲：
この調査レポートは、連続バイオプロセッシング市場を製品別（クロマトグラフィーシステムと消耗品、ろ過システムと装置、バイオリアクター、細胞培養培地、細胞株、緩衝液と試薬、その他の製品）、事業規模別（商業事業、臨床事業）、工程別（下流バイオ工程、上流バイオ工程）、 用途別（モノクローナル抗体、ワクチン、細胞・遺伝子治療、その他用途）、エンドユーザー別（製薬・バイオ医薬品企業、CRO（医薬品開発業務受託機関）・CMO（医薬品製造業務受託機関）、学術・研究機関）、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）にわたって分析をしています。本レポートでは、連続バイオプロセッシング市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、製品、ソリューション、主要戦略、提携、パートナーシップ、契約に関する洞察を提供します。連続バイオプロセッシング市場に関連する新発売、提携、買収、最近の動向を提供します。

レポート購入の主な利点：
本レポートは、連続バイオプロセッシング市場全体とそのサブセグメントについて、最も近似した収益数字を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのにも役立ちます。本レポートは、関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（バイオ医薬品の需要増加、CDMOとCMOの間での採用拡大、バッチ/フェドバッチモードに対する連続バイオプロセッシングの利点、革新的技術に対する有利な規制と政府支援、統合されたエンドツーエンドの連続バイオプロセッシングの出現）、阻害要因（小規模プレイヤーの参入を制限する高い設備投資と厳しい規制要件）、機会（新興経済国の高い成長可能性と連続バイオプロセッシングのPAT対応最適化）、市場の成長に影響を与える課題（既存の製造施設への統合と運用上の課題）の分析をしています。
- 製品開発/イノベーション： 連続バイオプロセッシング市場の新発売製品に関する詳細な洞察を記載しています。
- 市場開発： 有利な市場に関する包括的な情報 - 当レポートでは様々な地域の市場を分析しています。
- 市場の多様化： 連続バイオプロセッシング市場における新製品、未開拓地域、最近の開発、投資に関する詳細情報を提供します。
- 競合他社の評価：Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kühner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan)などが含まれます。

1.　イントロダクション
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　世界の連続バイオプロセッシング市場規模：製品別
7.　世界の連続バイオプロセッシング市場規模：事業規模別
8.　世界の連続バイオプロセッシング市場規模：プロセス別
9.　世界の連続バイオプロセッシング市場規模：用途別
10.　世界の連続バイオプロセッシング市場規模：エンドユーザー別
11.　世界の連続バイオプロセッシング市場規模：地域別
12.　競争環境
13.　企業情報
14.　付録

❖ レポートの目次 ❖

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS AND EXCLUSIONS 37
1.3 MARKET SEGMENTATION 38
FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION 38
1.4 YEARS CONSIDERED 38
1.5 CURRENCY CONSIDERED 39
1.6 LIMITATIONS 39
1.7 STAKEHOLDERS 39
1.8 RECESSION IMPACT 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 2 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 42
2.1.2 PRIMARY DATA 43
FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES 43
2.2 MARKET SIZE ESTIMATION 44
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022) 44
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS) 45
FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022) 45
2.2.1 INSIGHTS FROM PRIMARIES 46
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 46
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 47
2.3 GROWTH FORECAST 48
FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023–2028) 48
FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
2.4 DATA TRIANGULATION & MARKET BREAKDOWN 50
FIGURE 11 DATA TRIANGULATION METHODOLOGY 50
2.5 RESEARCH ASSUMPTIONS 51
2.6 RISK ANALYSIS 51
2.7 RECESSION IMPACT ANALYSIS 51
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 51
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 52
TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 52
3 EXECUTIVE SUMMARY 53
FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 53
FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION) 54
FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 54
FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 55
FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 56
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET 57
4 PREMIUM INSIGHTS 58
4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW 58
FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 58
4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT 59
FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 59
4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION 60
FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 60
4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2 MARKET DYNAMICS 62
TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS 62
5.2.1 DRIVERS 63
5.2.1.1 Rising demand for biopharmaceuticals 63
5.2.1.2 Growing adoption among CDMOs and CMOs 63
5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode 64
5.2.1.4 Favorable regulatory & government support for innovative technologies 65
5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing 65
5.2.2 RESTRAINTS 66
5.2.2.1 High capital investments to limit entry for smaller players 66
5.2.2.2 Stringent regulatory requirements 66
5.2.3 OPPORTUNITIES 67
5.2.3.1 High growth potential of emerging economies 67
5.2.3.2 PAT-enabled optimization of continuous bioprocessing 68
5.2.4 CHALLENGES 68
5.2.4.1 Integration into existing manufacturing facilities 68
5.2.4.2 Operational challenges 69
5.3 PRICING ANALYSIS 70
TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022) 70
TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022) 70
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS 71
5.5 VALUE CHAIN ANALYSIS 72
FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS 72
5.5.1 RESEARCH & PRODUCT DEVELOPMENT 72
5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY 73
5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES 73
5.6 SUPPLY CHAIN ANALYSIS 74
FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS 74
5.7 ECOSYSTEM ANALYSIS 75
FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET 75
TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE) 75
5.8 PATENT ANALYSIS 77
FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013–SEPTEMBER 2023) 77
5.9 KEY CONFERENCES AND EVENTS 78
TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023−2024) 78
5.10 REGULATORY LANDSCAPE 79
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.10.2 REGULATORY GUIDELINES 80
5.11 PORTER’S FIVE FORCES ANALYSIS 81
TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER’S FIVE FORCES ANALYSIS 81
5.11.1 THREAT OF NEW ENTRANTS 82
5.11.2 THREAT OF SUBSTITUTES 82
5.11.3 BARGAINING POWER OF SUPPLIERS 82
5.11.4 BARGAINING POWER OF BUYERS 82
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 82
5.12 TECHNOLOGY ANALYSIS 82
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 84
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS 84
5.14 KEY BUYING CRITERIA, BY END USER 85
FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET 85
6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT 86
6.1 INTRODUCTION 87
TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 87
6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES 88
6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET 88
TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 90
6.3 FILTRATION SYSTEMS AND DEVICES 90
6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET 90
TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 93
6.4 BIOREACTORS 93
6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND 93
TABLE 27 BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION) 95
6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS 96
6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH 96
TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
6.6 OTHER PRODUCTS 99
TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 101
7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION 102
7.1 INTRODUCTION 103
TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 103
7.2 COMMERCIAL OPERATIONS 103
7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET 103
TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION) 106
7.3 CLINICAL OPERATIONS 106
7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET 106
TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION) 108
8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS 109
8.1 INTRODUCTION 110
TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 110
8.2 DOWNSTREAM BIOPROCESS 110
8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET 110
TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION) 113
8.3 UPSTREAM BIOPROCESS 113
8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH 113
TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION) 115
9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION 116
9.1 INTRODUCTION 117
TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
9.2 MONOCLONAL ANTIBODIES 117
9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET 117
TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 120
9.3 VACCINES 120
9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET 120
TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 122
9.4 CELL & GENE THERAPY 123
9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND 123
TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 125
9.5 OTHER APPLICATIONS 125
TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 127
10 CONTINUOUS BIOPROCESSING MARKET, BY END USER 128
10.1 INTRODUCTION 129
TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 129
10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET 129
TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 132
10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 132
10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET 132
TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 135
10.4 ACADEMIC & RESEARCH INSTITUTES 135
10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH 135
TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 138
11 CONTINUOUS BIOPROCESSING MARKET, BY REGION 139
11.1 INTRODUCTION 140
TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION) 140
11.2 NORTH AMERICA 140
FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT 141
TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 142
TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 142
TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 143
TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 143
11.2.1 US 144
11.2.1.1 High biopharmaceutical R&D spending to drive market 144
TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 144
TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 145
TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 145
TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 145
TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 146
11.2.2 CANADA 146
11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market 146
TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147
TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 147
TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 147
TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148
TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 148
11.2.3 NORTH AMERICA: RECESSION IMPACT 148
11.3 EUROPE 149
TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150
TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 150
TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 150
TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 151
TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 151
11.3.1 GERMANY 151
11.3.1.1 Increasing initiatives for life sciences research to boost demand 151
TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 152
TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 153
TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 153
TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153
TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 154
11.3.2 UK 154
11.3.2.1 Favorable government support for biotech clusters to propel market 154
TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 155
TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 155
TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 155
TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 156
TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 156
11.3.3 FRANCE 156
11.3.3.1 Rising demand for mAbs and biologics to drive market 156
TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 157
TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 157
TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 157
TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158
TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 158
11.3.4 ITALY 158
11.3.4.1 Growth in pharma & biopharma industries to boost demand 158
TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159
TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 159
TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 160
TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160
TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 160
11.3.5 SPAIN 161
11.3.5.1 Increasing R&D funding by academic institutes to support market growth 161
TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161
TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 162
TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 162
TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162
TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 163
11.3.6 REST OF EUROPE 163
TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 164
TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 164
TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 164
TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 165
11.3.7 EUROPE: RECESSION IMPACT 165
11.4 ASIA PACIFIC 166
FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT 167
TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 168
TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 169
TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 169
TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 169
TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 170
11.4.1 CHINA 170
11.4.1.1 Government support and rising private investments to drive market growth 170
TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 171
TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 171
TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 171
TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172
TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 172
11.4.2 JAPAN 172
11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth 172
TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 173
TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 174
TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 174
TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 175
11.4.3 INDIA 175
11.4.3.1 Growth in pharmaceutical industry to boost demand 175
TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176
TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 176
TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 176
TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 177
TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 177
11.4.4 SOUTH KOREA 177
11.4.4.1 Rising focus on quality manufacturing practices to drive market 177
TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 178
TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 179
TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 179
TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179
TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 180
11.4.5 REST OF ASIA PACIFIC 180
TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 181
TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 181
TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 181
TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182
TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 182
11.4.6 ASIA PACIFIC: RECESSION IMPACT 182
11.5 LATIN AMERICA 183
TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 184
TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 184
TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 184
TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 185
11.5.1 BRAZIL 185
11.5.1.1 Rising focus on cell & therapy manufacturing to support market 185
TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 186
TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 186
TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 186
TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 187
11.5.2 MEXICO 187
11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth 187
TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 188
TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 188
TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 188
TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 189
11.5.3 REST OF LATIN AMERICA 189
TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 190
TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 190
TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 190
TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 191
11.5.4 LATIN AMERICA: RECESSION IMPACT 191

11.6 MIDDLE EAST & AFRICA 192
TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION) 192
TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 192
TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 193
TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 193
TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 193
TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 194
11.6.1 MIDDLE EAST 194
11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market 194
TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 195
TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 195
TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 195
TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 196
TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 196
11.6.2 AFRICA 196
11.6.2.1 Favorable initiatives for R&D investments to support market growth 196
TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 197
TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 197
TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 197
TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 198
TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION) 198
11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT 198
12 COMPETITIVE LANDSCAPE 199
12.1 OVERVIEW 199
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 199
12.3 REVENUE SHARE ANALYSIS 200
FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018−2022) 200
12.4 MARKET SHARE ANALYSIS 200
FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 201
TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY 201
12.5 COMPANY EVALUATION MATRIX 202
12.5.1 STARS 203
12.5.2 PERVASIVE PLAYERS 203
12.5.3 EMERGING LEADERS 203
12.5.4 PARTICIPANTS 203
FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 204
12.5.5 COMPANY FOOTPRINT ANALYSIS 205
TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022) 205
12.5.6 PRODUCT FOOTPRINT OF COMPANIES 206
TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS 206
12.5.7 REGIONAL FOOTPRINT OF COMPANIES 207
TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS 207
12.6 START-UP/SME EVALUATION MATRIX 208
12.6.1 PROGRESSIVE COMPANIES 208
12.6.2 RESPONSIVE COMPANIES 208
12.6.3 DYNAMIC COMPANIES 209
12.6.4 STARTING BLOCKS 209
FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022) 209
12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES 210
TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 210
TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES 211
12.7 COMPETITIVE SCENARIOS AND TRENDS 212
12.7.1 PRODUCT LAUNCHES 212
TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−OCTOBER 2023) 212
12.7.2 DEALS 212
TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020−OCTOBER 2023) 212
12.7.3 OTHER DEVELOPMENTS 213
TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020−OCTOBER 2023) 213
13 COMPANY PROFILES 214
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1 KEY PLAYERS 214
13.1.1 DANAHER CORPORATION 214
TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW 214
FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 215
13.1.2 SARTORIUS AG 218
TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW 218
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022) 219
13.1.3 THERMO FISHER SCIENTIFIC INC. 223
TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 223
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 224
13.1.4 REPLIGEN CORPORATION 227
TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW 227
FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022) 228
13.1.5 MERCK KGAA 231
TABLE 249 MERCK KGAA: BUSINESS OVERVIEW 231
FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022) 232
13.1.6 3M COMPANY 235
TABLE 250 3M COMPANY: BUSINESS OVERVIEW 235
FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022) 236
13.1.7 GETINGE AB 238
TABLE 251 GETINGE AB: BUSINESS OVERVIEW 238
FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022) 239
13.1.8 EPPENDORF SE 241
TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW 241
FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022) 242
13.1.9 CORNING INCORPORATED 244
TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW 244
FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022) 245
13.1.10 ENTEGRIS 246
TABLE 254 ENTEGRIS: BUSINESS OVERVIEW 246
FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022) 247
13.1.11 FUJIFILM HOLDINGS CORPORATION 249
TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 249
FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 250
13.1.12 MEISSNER FILTRATION PRODUCTS, INC. 252
TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW 252
13.1.13 KÜHNER AG 254
TABLE 257 KÜHNER AG: BUSINESS OVERVIEW 254
13.1.14 ESCO LIFESCIENCES GROUP 256
TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW 256
13.1.15 SATAKE MULTIMIX CORPORATION 257
TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW 257
13.2 OTHER PLAYERS 258
13.2.1 BIONET 258
13.2.2 STOBBE GROUP 259
13.2.3 BBI-BIOTECH GMBH 260
13.2.4 OMNIBRX BIOTECHNOLOGIES 260
13.2.5 CELL CULTURE COMPANY, LLC 261
13.2.6 PIERRE GUÉRIN 261
13.2.7 SOLIDA BIOTECH GMBH 262
13.2.8 ZELLWERK GMBH 262
13.2.9 3D BIOTEK, LLC 263
13.2.10 FIBERCELL SYSTEMS INC. 263
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
14 APPENDIX 264
14.1 DISCUSSION GUIDE 264
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 269
14.3 CUSTOMIZATION OPTIONS 271
14.4 RELATED REPORTS 271
14.5 AUTHOR DETAILS 273

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 連続バイオプロセッシングのグローバル市場予測（～2028）：クロマトグラフィー、ろ過、バイオリアクター、培地(Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
グローバルリサーチ調査資料のイメージグローバルリサーチ調査資料のイメージ
◆関連リサーチレポート◆
  • 世界の連続バイオプロセス市場2023-2030：製品別（ろ過システム・消耗品、クロマトグラフィーシステム・消耗品、バイオリアクター、滅菌器、遠心分離機、その他）、用途別（商業用、ワクチン、mAb生産、組換えタンパク質生産、細胞・遺伝子治療生産、研究開発）、エンドユーザー別、地域別
  • 世界の細胞培養市場：製品別（消耗品（培地、血清、試薬）、容器（ローラーボトル、セルファクトリー）、装置（バイオリアクター、遠心分離機、インキュベーター））、用途別、エンドユーザー別
  • 世界の治療薬物モニタリング市場：製品別（消耗品、機器-免疫測定装置、クロマトグラフィー＆MS検出器、臨床化学分析装置）、技術別、薬物クラス別、エンドユーザー別、地域別
  • 患者腫瘍移植/PDXモデルの世界市場予測（～2028）：種類別、移植方法別、腫瘍種類別、用途別、エンドユーザー別
  • シングルユースバイオリアクター（SUB）の世界市場予測（～2028）：製品別、種類別、細胞タイプ別、分子別、エンドユーザー別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆